Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer

BACKGROUND: Currently available third- or later-line therapy for metastatic colorectal cancer (mCRC) is limited in its efficacy, with a weak survival benefit in patients who progressed after two or more lines of standard therapy. Our retrospective study aimed to explore the value of bevacizumab plus...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Onco Targets Ther
Main Authors: Yang, Qiong, Yin, Chenxi, Liao, Fangxin, Huang, Yuanyuan, He, Wenzhuo, Jiang, Chang, Guo, Guifang, Zhang, Bei, Xia, Liangping
Format: Artigo
Sprog:Inglês
Udgivet: Dove Medical Press 2015
Fag:
Original Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4562721/
https://ncbi.nlm.nih.gov/pubmed/26366095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S88679
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker